Workflow
Profound Medical (PROF) Reports Q4 Loss, Misses Revenue Estimates
PROFProfound(PROF) ZACKS·2025-03-06 23:40

Company Performance - Profound Medical reported a quarterly loss of 0.20pershare,betterthantheZacksConsensusEstimateofalossof0.20 per share, better than the Zacks Consensus Estimate of a loss of 0.30, and an improvement from a loss of 0.42pershareayearago,representinganearningssurpriseof33.330.42 per share a year ago, representing an earnings surprise of 33.33% [1] - The company posted revenues of 4.18 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 0.55%, but showing growth from year-ago revenues of 2.01million[2]−Overthelastfourquarters,thecompanyhassurpassedconsensusEPSestimatestwotimes,buthasnotbeenabletobeatconsensusrevenueestimates[2]StockOutlook−ProfoundMedicalshareshavedeclinedapproximately2.42.01 million [2] - Over the last four quarters, the company has surpassed consensus EPS estimates two times, but has not been able to beat consensus revenue estimates [2] Stock Outlook - Profound Medical shares have declined approximately 2.4% since the beginning of the year, compared to a decline of 0.7% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -0.27 on revenues of 3.8million,andforthecurrentfiscalyear,itis−3.8 million, and for the current fiscal year, it is -1.07 on revenues of $24.09 million [7] - The estimate revisions trend for Profound Medical is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Drugs industry, to which Profound Medical belongs, is currently ranked in the bottom 46% of over 250 Zacks industries, suggesting that the outlook for the industry can significantly impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]